The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Primary focal hyperhidrosis interferes with daily activities. Limited efficacy, costs, side
effects and complications are issues of concern for most current therapeutic modalities. In
this study the invetigators aim to evaluate the efficacy of topical oxybutynin 10% gel in
treating primary focal hyperhidrosis. 60 patients with primary focal hyperhidrosis will be
recruited. Topical oxybutynin 10% gel will be assigned to the right or left axilla, palm or
sole and a placebo compound to the contralateral side for a total of 30 days. The
Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI)
questionnaires will be administered before and after treatment, and 2 noninvolved blinded
physicians will score the results using starch-iodine tests. The participants will grade the
sweat reduction on both sides and rated their satisfaction.